Galecto will use the proceeds to conduct a phase 2/3 clinical study of inhaled TD139, a potent and selective inhibitor of galectin - 3, in idiopathic pulmonary f ibr osis (IPF), a chronic and se vere ...
Read moreLa compañía biofarmacéutica AbilityPharma acaba de cerrar una ronda de financiación por valor superior al 1.230.000 euros a través de la plataforma de crowdfunding Capital Cell. Con esta cifra...
Read moreDuring 2019, GENESIS Ventures aims to invest in 10 more projects or companies to complete its €1.2 million investment fund. The tickets vary between €50,000 to €100,000 per investment
Read moreOna Therapeutics, spin-off del IRB Barcelona e ICREA, ha sido fundada por los investigadores Salvador Aznar-Benitah y Valerie Vanhooren tras la inversión liderada por Sabadell Asabys. La empresa, co...
Read moreAM-Pharma B.V. (‘AM-Pharma, the Company’), a clinical stage biopharmaceutical company, leading in the development of a treatment for acute kidney injury (AKI) with its innovative recombinant human...
Read moreAsabys Partners (“Asabys”), a Pan-European Venture Capital firm specialized in investments in the life sciences and health sectors, and Alantra, an investment banking and asset management firm...
Read moreEl equipo ejecutivo se refuerza con la incorporación de Maribel Berges como Directora General ascendiendo Carles Domènech a la Presidencia Ejecutiva
Read moreVersantis, a pharmaceutical company focused on the development of products addressing a high unmet medical need in the diagnosis, prevention, and treatment of liver diseases, today announces the closi...
Read moreThe conference on health innovation Innovation for value, held on November 8 in Barcelona, has analyzed the opportunities offered by technological advances in the field of health. The conference, orga...
Read moreAnaconda Biomed S.L., a medical technology company developing next-generation thrombectomy systems for the treatment of ischemic stroke, has closed €20 million in new funding. The funding w...
Read moreAyer concluyó el aumento de capital anunciado por ATRYS HEALTH S.A (“ATRYS”) el pasado 23 de octubre.
Read moreAnte el continuo crecimiento del sector salud en el país y las oportunidades que se derivan de éste, la consultora de negocios en el sector salud GENESIS Biomed y la boutique de M&A CREA Inver...
Read more